Sign up to save your data!
Some tips to help get started:
Processing...
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial involves patients aged 18 and over with advanced solid tumors exhibiting chromosomal instability, such as high-grade serous ovarian cancer, squamous non-small cell lung cancer, and triple negative breast cancer, who have limited therapeutic options. It assesses VLS-1488, an oral KIF18A inhibitor targeting mitotic processes in cancer cells, administered in 28-day cycles to determine its safety, tolerability, and efficacy.
ClinicalTrials.gov ID: NCT05902988
HealthScout AI summary: The trial involves patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory non-small cell lung cancer, assessing the safety and efficacy of TUB-040, an antibody-drug conjugate targeting NaPi2b with a topoisomerase I inhibitor, administered every three weeks.
ClinicalTrials.gov ID: NCT06303505
HealthScout AI summary: The clinical trial investigates PRT7732, an oral SMARCA2 degrader, in approximately 104 patients with advanced or metastatic solid tumors harboring SMARCA4 mutations, who have progressed on or are ineligible for standard therapy. The study focuses on establishing safety, tolerability, pharmacokinetics, and preliminary efficacy.
ClinicalTrials.gov ID: NCT06560645
HealthScout AI summary: This trial is for patients with advanced or metastatic solid tumors such as ovarian cancer, NSCLC, pancreatic adenocarcinoma, endometrial cancer, colorectal cancer, and mesothelioma, evaluating PF-08052666/SGN-MesoC2, an antibody-drug conjugate targeting mesothelin-expressing cells with a topoisomerase 1 inhibitor.
ClinicalTrials.gov ID: NCT06466187
HealthScout AI summary: This trial involves adult patients with advanced EGFR-expressing solid tumors that are unresectable or metastatic, including colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and pancreatic ductal adenocarcinoma. The study examines the safety and efficacy of SGN-EGFRd2, a bispecific antibody targeting EGFR and γ9δ2 T cell receptors, as monotherapy.
ClinicalTrials.gov ID: NCT05983133
HealthScout AI summary: The trial evaluates the investigational antibody-drug conjugate XB010, which targets the 5T4 antigen to inhibit tumor growth, in adults with locally advanced or metastatic solid tumors who lack alternative treatment options; it assesses XB010 as both a monotherapy and in combination with pembrolizumab across various tumor types including non-small cell lung cancer, hormone-receptor-positive and triple-negative breast cancer, head and neck, and esophageal squamous cell cancers.
ClinicalTrials.gov ID: NCT06545331
HealthScout AI summary: This trial investigates the safety and efficacy of OKN4395, a dual antagonist of EP2 and EP4 prostanoid receptors, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including sarcoma, NSCLC, mesothelioma, and HNSCC, who have exhausted standard treatment options.
ClinicalTrials.gov ID: NCT06789172
HealthScout AI summary: This trial is for adult patients with advanced or metastatic solid tumors that have MTAP deletion, evaluating TNG456, a PRMT5 inhibitor, alone and with abemaciclib, a CDK4/6 inhibitor. The study is assessing safety, tolerability, and antitumor activity, focusing on those who have progressed on or are unsuitable for standard therapy.
ClinicalTrials.gov ID: NCT06810544
HealthScout AI summary: The trial involves adult patients with advanced solid tumors harboring KRAS mutations who have progressed on, are intolerant to, or declined standard therapies, and maintains an ECOG performance status of 0 or 1. It evaluates the safety and tolerability of ALTA3263, an orally administered, isoform-selective KRAS inhibitor targeting both active and inactive KRAS mutations, in a dose escalation and expansion design.
ClinicalTrials.gov ID: NCT06835569
HealthScout AI summary: This trial involves adult patients with advanced solid tumors, including specific types like hepatocellular carcinoma and non-small cell lung cancer, who have exhausted standard treatments, and assesses the safety and clinical activity of Decoy20, a Toll-like receptor agonist immunotherapy, both alone and in combination with the PD-1 inhibitor tislelizumab.
ClinicalTrials.gov ID: NCT05651022
